<DOC>
	<DOC>NCT00222053</DOC>
	<brief_summary>Principal objective is to evaluate the impact of Thalidomide to prolong the duration of response after autologous transplantation for myeloma</brief_summary>
	<brief_title>IFM 99-02 Thalidomide in Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>de novo myeloma according to Durie and Salmon classification stage II, III and stage I with a lytic bone lesion patients from 18 to 65 years old beta2microglobulin &lt; 3 mg/l or del13 absent signed informed consent eligible for transplantation peripheral neurological toxicities uncontrolled or severe cardiovascular disease other malignancy except basocellular carcinoma or FIGO stage I carcinoma of the cervix patient who received biphosphonate during the last 60 days renal failure definited as creatinine &gt; 150 µmol/l patient with obvious vascular cerebral medical history liver dysfunction definited as bilirubin &gt; 35 µmol/l or ASAT, ALAT, PAL &gt; 4N respiratory dysfunction HIV + Patient who refused to use an acceptable barrier method for contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Autologous transplantation</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Thalidomide</keyword>
</DOC>